This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Walker, J. D Search for Related Content Social Bookmarking                         What's this?

Review: Angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in diabetic renal disease

Department of Diabetes, Royal Infirmary, Edinburgh, EH3 9YW, UK, james.walker{at}luht.scot.nhs.uk

In mortality terms diabetic nephropathy is the most important microvascular complication of diabetes. Even a small elevation in urinary albumin loss (microalbuminuria) is an independent predictor of end-stage renal failure (ESRF) and death. Detection, confirmation and treatment of diabetic nephropathy are mandatory aspects of diabetes care. Over the last decade a considerable body of evidence has built up suggesting that angiotensin-converting enzyme (ACE) inhibitors are superior to other antihypertensive agents in terms of both renal and overall vascular protection. More recently a number of important studies have reported the beneficial effects of angiotensin receptor antagonists (AIIA) in patients with type 2 diabetes at the stages of microalbuminuria and proteinuria. To date no large studies have directly compared ACE inhibitors with AIIA in patients with diabetic nephropathy. However, given the current state of knowledge, evidence-based therapeutic decisions are possible for individual patients with diabetic nephropathy.

Key Words: angiotensin-converting enzyme (ACE) inhibitors • angiotensin receptor antagonists (AIIA) • diabetic renal disease • hypertension.

References

• Parving HH, Hommel E., Mathiesen E. et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. BMJ 1988;296:156-60.[Abstract/Free Full Text]
• Orchard TJ, Dorman JS, Maser RE et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990;39:1116-23.[Abstract]
• Eurodiab Iddm Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 1994;37:278-85.[Web of Science][Medline] [Order article via Infotrieve]
• Messent JW, Elliott TG, Hill RD et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 1992;41:836-9.[Web of Science][Medline] [Order article via Infotrieve]
• Hovind P., Rossing P., Tarnow L. et al. Progression of diabetic nephropathy. Kidney Int 2001;59:702-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wang SL, Head J., Stevens L. et al. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The world health organization multinational study of vascular disease in diabetes. Diabetes Care 1996;19:305-12.[Abstract]
• Mogensen CE Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-60.[Abstract]
• Nielsen FS, Rossing P., Gall MA et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997;46:1182-8.[Abstract]
• Mattock MB, Morrish NJ, Viberti G. et al. Prospective study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes 1992;41:736-41.[Abstract]
• Schmitz A., Vaeth M. Microalbuminuria: a major risk factor in non-insulin dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med 1988;5:126-34.[Web of Science][Medline] [Order article via Infotrieve]
• Zatz R., Dunn BR, Meyer TW et al. Prevention of diabetic glomerulopathy by pharmacological amiloration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30.[Web of Science][Medline] [Order article via Infotrieve]
• Leehey DJ, Singh AK, Alavi N. et al. Role of angiotensin II in diabetic nephropathy. Kidney Int 2000;58 (S77):S93-8.
• Niskanen L., Hedner T., Hansson L. et al. for the CAPPP Study group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/ß-blocker regimen. A subanalysis of the Captopril Prevention Project. Diabetes Care 2001;24:2091-6.[Abstract/Free Full Text]
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.[Abstract/Free Full Text]
• Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kasiske BL, Kalil RSN, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118:129-38.[Abstract/Free Full Text]
• The ACE Inhibitors in Diabetic Nephropathy Trials Group. Should all patients with type 1 diabetes and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001;134:370-9.[Abstract/Free Full Text]
• Kshirsagar AV, Joy MS, Hogan SL et al. Effect of ACE inhibitors in diabetic and non-diabetic chronic renal disease: a systematic overview of randomised placebo-controlled trials. Am J Kid Dis 2000;35:695-707.[Web of Science][Medline] [Order article via Infotrieve]
• Mann JFE, Gerstein HC, Pogue J. et al. for the HOPE investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomised trial. Ann Intern Med 2001;134:629-36.[Abstract/Free Full Text]
• Parving HH, Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
• Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.[Abstract/Free Full Text]
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
• Brenner BM, Cooper ME, De Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
• Valabhji J., Robinson S., Poulter C. et al. Prevalence of renal artery stenosis in subjects with type 2 diabetes and coexistent hypertension. Diabetes Care 2000;23:539-43.[Abstract]
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.[Abstract/Free Full Text]
• Muirhead N., Feagan BF, Mahon J. et al. The effects of valsartan and captopril in reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res 1999;60:650-60.[CrossRef]
• Mogensen CE, Neldam S., Tikkanen I. et al. for the CALM study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.[Abstract/Free Full Text]
• Scottish Intercollegiate Guidelines Network. Management of Diabetes: a national clinical guideline. Edinburgh: SIGN 55, 2001. www.sign.ac.uk

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 2, 81-84 (2002)
DOI: 10.1177/14746514020020020301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Walker, J. D Search for Related Content Social Bookmarking                         What's this?